Evidence map›Paper›PMID 38149252›Full record

ReviewFrontiers in immunology2023

Mitochondrial-regulated Tregs: potential therapeutic targets for autoimmune diseases of the central nervous system.

Aoya Han, Tingting Peng, Yinyin Xie, Wanwan Zhang, Wenlin Sun, Yi Xie, Yunqing Ma, Cui Wang, Nanchang Xie

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. The Neuroimmunology of Autism.Molecular neurobiology · 2025
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aoya Han *Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tingting Peng *Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yinyin XieDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wanwan ZhangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenlin SunDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yi XieDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yunqing MaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Cui WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Nanchang XieDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T cells (Tregs) can eliminate autoreactive lymphocytes, induce self-tolerance, and suppress the inflammatory response. Mitochondria, as the energy factories of cells, are essential for regulating the survival, differentiation, and function of Tregs. Studies have shown that patients with autoimmune diseases of the central nervous system, such as multiple sclerosis, neuromyelitis optica spectrum disorder, and autoimmune encephalitis, have aberrant Tregs and mitochondrial damage. However, the role of mitochondrial-regulated Tregs in autoimmune diseases of the central nervous system remains inconclusive. Therefore, this study reviews the mitochondrial regulation of Tregs in autoimmune diseases of the central nervous system and investigates the possible mitochondrial therapeutic targets.

Indexed as

Autoimmune DiseasesMultiple SclerosisCentral Nervous SystemHumansMitochondriaSelf Toleranceautoimmune diseasescentral nervous systemFoxp3mitochondriaregulatory T cellself-tolerance

Identifiers

PMID38149252
PMCPMC10749924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.